<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02678416</url>
  </required_header>
  <id_info>
    <org_study_id>MNK14504055</org_study_id>
    <nct_id>NCT02678416</nct_id>
  </id_info>
  <brief_title>A Study Comparing Reduction in Pain Intensity Following IV or Oral Acetaminophen</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Double-Blind, Two-Part, Cross-over Study to Compare the Reduction in Pain Intensity After Single-Dose Administration of IV or Oral Acetaminophen and IV Morphine by Using UVB or IDC Pain Models</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare reduction in pain intensity provided by IV or oral acetaminophen using UVB pain model
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sum of change in pain intensity from baseline in UVB pain model</measure>
    <time_frame>0 to 6 Hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sum of change in pain threshold from baseline in IDC pain model</measure>
    <time_frame>0 to 4.5 Hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>IV Acetaminophen/Placebo tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acetaminophen, 100 mL of 1,000 mg/100 mL will be administered IV (15 minute infusion) and 2 placebo tablets will be administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Placebo/Acetaminophen tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An IV placebo 100 mL (15 minute infusion of saline) and 2 acetaminophen tablets (500 mg/tablet) will be administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Placebo/Placebo tablets</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>An IV placebo 100 mL (15 minute infusion of saline) and 2 placebo tablets will be administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Morphine/Placebo tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>An IV morphine (0.1 mg/kg) in 100 mL saline (15 minute infusion of saline) and 2 placebo tablets will be administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Acetaminophen</intervention_name>
    <description>IV formulation</description>
    <arm_group_label>IV Acetaminophen/Placebo tablets</arm_group_label>
    <other_name>Ofirmev</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Morphine</intervention_name>
    <description>IV formulation</description>
    <arm_group_label>IV Morphine/Placebo tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo tablet</intervention_name>
    <description>tablet</description>
    <arm_group_label>IV Acetaminophen/Placebo tablets</arm_group_label>
    <arm_group_label>IV Placebo/Placebo tablets</arm_group_label>
    <arm_group_label>IV Morphine/Placebo tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen tablets</intervention_name>
    <description>oral formulation</description>
    <arm_group_label>IV Placebo/Acetaminophen tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>IV Placebo</intervention_name>
    <description>IV formulation</description>
    <arm_group_label>IV Placebo/Acetaminophen tablets</arm_group_label>
    <arm_group_label>IV Placebo/Placebo tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Subject must have a health status of &quot;healthy&quot; assessed by the investigator and
             defined as no clinically significant deviation from normal medical history, physical
             examination, vital signs, and clinical laboratory determinations.

          2. Subject must be male, Caucasian, between 18 and 55 years of age (inclusive) at the
             time of the screening.

          3. Subject must have a body mass index (BMI) ≥ 19.0 and ≤ 30.0 kg/m2 with a minimum
             weight of 110 pounds (50 kg) at screening.

        Exclusion Criteria

          1. A positive test result for human immunodeficiency virus (HIV), hepatitis B (surface
             antigen), or hepatitis C virus antibody at Screening.

          2. A history of any drug allergy, hypersensitivity, or intolerance to acetaminophen,
             morphine, or capsaicin or to any of the excipients in the IV or oral formulations
             used.

          3. A positive test result for drugs of abuse, alcohol, or cotinine.

          4. Fitzpatrick Skin Type V or VI (based on a Skin Type score of greater than 30.

          5. A history of conditions which might be specifically contraindicated or require caution
             to be used during the administration of any drug in the study.

          6. Any other medical, psychiatric and/or social reason for exclusion as determined by the
             investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pharmaceuticals Research Associates, Inc. (PRA)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2016</study_first_submitted>
  <study_first_submitted_qc>February 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2016</study_first_posted>
  <last_update_submitted>August 9, 2016</last_update_submitted>
  <last_update_submitted_qc>August 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>comparison</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 28, 2017</submitted>
    <returned>July 28, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

